Main menu

Randy Scott, Sean George

Jan 09, 2017

Invitae President and Chief Operating Officer Sean George will take over as CEO, effective immediately, the company announced. Current CEO Randy Scott will continue full time at Invitae serving as executive chairman of the board of directors. The changes come as the company is focused on driving global growth in genetic testing. Previously, George was a co-founder and CEO of genetic analysis startup Locus Development. Scott previously served as executive chairman at Genomic Health and chief operating officer at personal genomics firm Navigenics.

More Like This

Feb 20, 2018

Robert Hugin

Robert Hugin has resigned as a director at Danaher, following his decision to run for the US Senate representing New Jersey. He will run as a Republican against Sen. Robert Menendez, a Democrat. According to Politco, Hugin is a supporter of President Donald Trump. He was previously the executive chairman of Celgene before retiring from that position in January, and he was CEO of the company from June 2010 to March 2016.

Feb 16, 2018

John Goetz

John Goetz, the executive vice president and chief operating officer of Bio-Rad Laboratories, will retire and resign from his position effective March 30, 2018, but will remain available for consultation after his employment ends if a successor has not yet been named. Goetz has been with Bio-Rad for more than 40 years and was named COO in 2014.

Feb 09, 2018

Eutillio Buccilli, Paul Kasian

Genetic Technologies, a Melbourne, Australia-based molecular diagnostics company, said this week that Eutillio Buccilli will step down as CEO. Buccilli joined the company in June 2014 as CFO and was appointed CEO in February 2015. Paul Kasian has been appointed interim CEO while the company undertakes an executive search for a permanent CEO.

Feb 07, 2018

Alberto Gutierrez

Alberto Gutierrez has joined NDA Partners as an expert consultant. The company provides consulting services in product development and regulation of medical products. Gutierrez is the former director, Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health. He spent 25 years at the agency before leaving last September.

Feb 06, 2018

Jim LaFrance

Jim LaFrance has joined the board of platelet activiation technology firm LightIntegra Technology. LaFrance is currently chairman of the board at Vermillion, executive chairman of Bioarray Genetics, and he serves on the board of HTG Molecular and Personal Genome Diagnostics. He was interim CEO of Vermillion, CEO of Omnyx within GE Healthcare, CEO and president of LaFrance Consulting, and head of international commercial operations at Ventana, now part of Roche.

Feb 05, 2018

Darlene Depula-Hicks, John Sprague

T2 Biosystems announced today that Darlene Deptula-Hicks has resigned as CFO, effective immediately. In addition, T2 Biosystem's board of directors have appointed John Sprague to serve as the firm's CFO. Prior to T2 Biosystems, Sprague served as CFO at Caliber Imaging & Diagnostics. Before Caliber, he also spent six years working in several financial positions at GE Healthcare. Mr. Sprague recevied his bachelor's degree in accounting from Boston College.

Feb 05, 2018

Panna Sharma

Cancer Genetics announced that its CEO Panna Sharma will be stepping down as president, director, and CEO of the firm. The company’s board has appointed current COO John Roberts as the interim CEO. Sharma will provide consulting services during the transition period.

Feb 02, 2018

Matthew McGrew, Daniel Comas

Danaher announced Matthew McGrew will become the firm's CFO, effective Jan. 1, 2019. He will replace Daniel Comas, who will continue as an executive vice president and a member of the Office of the Chief Executive as he begins a gradual transition to retirement. McGrew joined Danaher in 2004 as director M&A Finance. He currently is Group CFO of Danaher's Diagnostics and Dental platforms. Comas has been with Danaher since 1991 and became its CFO in 2005.

Feb 02, 2018

Aradhana Sarin

Orasure has appointed Aradhana Sarin to its board of directors. She will serve as a Class II director with an initial term expiring at the company's 2020 annual shareholders meeting. She will also serve on the audit committee and nominating and corporate governance committee of the board. Sarin is currently SVP, Head of Corporate Business Development and Strategy for Alexion Pharmaceuticals. She also is Co-Chair of the executive management committee overseeing science and innovation at Alexion. Prior to Alexion, Sarin was at Citi Global Banking and was the Managing Director of Healthcare Corporate & Investment Banking.

Jan 30, 2018

Deepak Nath

Siemens Healthineers has appointed Deepak Nath as president of laboratory diagnostics effective Feb. 1. He succeeds Franz Walt, who served as president from 2014 through 2017 and led the business during its launch of the Atellica immunoassay and clinical chemistry solution.

Nath brings 20 years of leadership experience in healthcare, including general management, strategy, R&D, commercial operations, and change management.

For the past three years, Nath served as president of Abbott’s vascular division and as an executive officer of the company.

Jan 26, 2018

Gregory Henderson

Gregory Henderson has resigned from his position as president of BioReference Laboratories, effective immediately. The company has begun a search for his replacement. In the interim, a committee of senior management will assume operational responsibilities. In announcing Henderson's departure, Phillip Frost, chairman and CEO of Opko Health, the parent company of BioReference Laboratories, said the company is seeking an executive with appropriate industry experience and leadership skills focused on expanding BioReference's role in the diagnostic space.

Jan 24, 2018

Nalini Murdter

JSR Life Sciences has appointed Nalini Murdter as president and CEO of MBL International (MBLI), a JSR subdivision that provides products for life sciences research and clinical diagnostics, specializing in reagents and assays for detecting biomarkers and analyzing disease pathways. Murdter previously served as vice president of commercial operations and business development at MBLI, and managing director of the diagnostics and research products division at JSR. She was previously chief business offices a NanoString Technologies, and held several senior management positions in business development, strategy, and marketing at Agilent Technologies.

Jan 19, 2018

Tadd Lazarus

Clinical Genomics has appointed Tadd Lazarus as chief medical officer. Lazarus most recently served as senior vice president and chief medical officer for Luminex. He also served as chief medical officer and head of medical and scientific affairs, reimbursement, and public policy at Qiagen from 2013 to 2016. Lazarus also was previously employed by Gen-Probe (now Hologic) as chief medical officer and VP of clinical affairs. He began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as director of medical and scientific affairs, and then as the North American medical director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology businesses.

Jan 18, 2018

Douglas Sites

Precipio has appointed Douglas Sites to the newly created position of vice president of sales, where he will be responsible for leading sales of the firm's cancer diagnostic services to oncologists and hospitals. The company also said that it plans to triple the size of its sales force in 2018, focusing first on small to midsize oncology practices and hospitals. Sites has spent the last 20 years in life sciences and cancer diagnostics, including roles as director of sales at Plus Diagnostics and VP of sales at Asuragen.

Jan 16, 2018

Avi Pelossof

Avi Pelossof has been appointed president and CEO of Immucor, effective immediatley. Pelossof succeds CEO Jeffrey Binder, who will remain chairman of Immucor's board of directors. Pelossof joins Immucor from Alere, now part of Abbott, where he served as global president for infectious disease. With over 20 years of experience in the diagnostic space, Pelossof has also held positions at Chembio Diagnostic Systems and Citibank.